ASCO 2024 Poster for Trial #22-26

A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click the above link to view the abstract.

ASCO 2024 Poster for Trial 22-26

ASCO 2024 Poster for Trial 22-26

Click here to view the ASCO 2024 Poster for Trial 22-26 in Full-Size.

Related Abstracts

Discover more abstracts for our trials.

Preliminary Clinical Activity of RMC-6236, a First-in-Class, RAS-Selective, Tri-Complex RASMULTI(ON) Inhibitor in Patients with KRAS-Mutant Pancreatic Ductal Adenocarcinoma (PDAC) and Non-Small Cell Lung Cancer (NSCLC)

Aug 23, 2024

Dr. Minal Barve

STX-478, a mutant-selective PI3Kαinhibitor clinical candidate with a best-in-class profile: Pharmacology and therapeutic activity as monotherapy and in combination in breast cancer xenograft models

Aug 21, 2024

Dr. Douglas Orr

BT8009-100 Phase I/II Study of Novel Bicyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

Aug 21, 2024

Dr. Minal Barve
See All Posts